What question did this study set out to answer?

This research aims to understand how circulating methylated tumor DNA can indicate the likelihood of cancer recurrence after lung surgery.

March 21, 2026ESMO Open0 citationsOpen Access

243P Plasma circulating methylated tumor DNA as a predictor of recurrence after lung cancer surgery with curative intent

JLJ. LeeVejle Sygehus THT.F. HansenVejle Sygehus THT.S. HansenVejle Sygehus

Key Points

This research aims to understand how circulating methylated tumor DNA can indicate the likelihood of cancer recurrence after lung surgery.
Analyzed plasma circulating methylated tumor DNA levels in lung cancer patients post-surgery
Examined recurrence patterns in different molecular mutations (EGFR vs. ALK)
Utilized clinical trial data to correlate tumor biology with recurrence time
EGFR mutations show delayed recurrence patterns compared to ALK rearrangements
Both subgroups have similar recurrence-free survival rates initially
Postoperative surveillance strategies should differ based on molecular mutation status

Abstract

according to sex.In both molecular mutational subgroups stage remained a strong prognostic determinant.Conclusions: EGFR-and ALK-driven tumours exhibit distinct recurrence dynamics after R0 resection: Although RFS and risk were similar among the two subgroups, EGFR-mutated disease shows delayed recurrence, whereas ALK-rearranged disease shows early recurrence risk.These findings highlight the relevance of molecular status for tailoring postoperative surveillance.Clinical trial identification: NCT02941458.

AI에게 질문

Bookmark

View Full Paper